Abstract
Current pharmacological treatments for eating disorders and obesity are of limited value and thus the identification of novel targets is highly needed to enhance the development of more effective drugs. Among the bottlenecks limiting the introduction of new medicines is the reported heterogeneity of these diseases, which makes it difficult to find drugs with broad activity and the lack of animal models with translational validity, especially in the case of anorexia nervosa. Some kinds of obesity and eating disorders can be classified within the pathologies affecting the brain reward system together with drug addiction and others, and therefore specific treatments in these cases can be directed to restore normal function in brain reward pathways. Target identification in this field can greatly benefit from the combined application of genomic/proteomic techniques and robust animal models of reward deficits.
Keywords: Obesity, eating disorders, reward deficit, addiction
Current Pharmaceutical Design
Title: Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction
Volume: 17 Issue: 5
Author(s): Luis F Alguacil, Elisabet Salas and Carmen Gonzalez-Martin
Affiliation:
Keywords: Obesity, eating disorders, reward deficit, addiction
Abstract: Current pharmacological treatments for eating disorders and obesity are of limited value and thus the identification of novel targets is highly needed to enhance the development of more effective drugs. Among the bottlenecks limiting the introduction of new medicines is the reported heterogeneity of these diseases, which makes it difficult to find drugs with broad activity and the lack of animal models with translational validity, especially in the case of anorexia nervosa. Some kinds of obesity and eating disorders can be classified within the pathologies affecting the brain reward system together with drug addiction and others, and therefore specific treatments in these cases can be directed to restore normal function in brain reward pathways. Target identification in this field can greatly benefit from the combined application of genomic/proteomic techniques and robust animal models of reward deficits.
Export Options
About this article
Cite this article as:
F Alguacil Luis, Salas Elisabet and Gonzalez-Martin Carmen, Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction, Current Pharmaceutical Design 2011; 17 (5) . https://dx.doi.org/10.2174/138161211795164158
DOI https://dx.doi.org/10.2174/138161211795164158 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism The Importance of the Adenosine A2A Receptor-Dopamine D2 Receptor Interaction in Drug Addiction
Current Medicinal Chemistry Expression Analysis of 4-Hydroxynonenal Modified Proteins in Schizophrenia Brain; Relevance to Involvement in Redox Dysregulation
Current Proteomics Meet Our Co-Editor
Cardiovascular & Hematological Agents in Medicinal Chemistry Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets Prevalence and Factors Associated With Low Aerobic Performance Levels in Adolescents: A Systematic Review
Current Pediatric Reviews Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Novel Medication Targets for the Treatment of Alcoholism: Preclinical Studies
Recent Patents on CNS Drug Discovery (Discontinued) Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling
Current Neuropharmacology Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Toxic Effects of Palladium Compounds on the Isolated Rat Heart
Medicinal Chemistry Preparation of Potent Leptin Receptor Antagonists and Their Therapeutic Use in Mouse Models of Uremic Cachexia and Kidney Fibrosis
Current Pharmaceutical Design Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS
Current Neuropharmacology Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology African Americans with Obsessive-Compulsive Disorder: An Update
Current Psychiatry Reviews Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment
Current Medicinal Chemistry Structural and Functional Neuroimaging in Alzheimers Disease: An Update
Current Topics in Medicinal Chemistry